What To Expect at the 2nd World RNA-Based Therapeutics & Vaccines Summit South Korea
행사 소개
Driven by South Korea’s government making strategic investments in mRNA platforms and growing collaboration between global pharma and local biotech innovators, the field is experiencing renewed development momentum. This is placing the region as a key hotspot for global mRNA innovation and interest.
Uniquely positioned as the industry’s most comprehensive biopharma forum, the 2nd World RNA-Based Therapeutic & Vaccine Summit South Korea brings together global and local leaders to share first-hand insights into cutting-edge mRNA modalities, delivery technologies, and manufacturing excellence, to progress mRNA medicines to patients faster.
Join 90 leading players from C-Suite to Scientists across R&D, manufacturing, and business development. From large pharma including Sanofi, Eisai, and Meiji Seika Pharma to brand new biotechs such as Lemonex Bio, AceRNA Technologies, and BreezeBio, this is your forum to build future collaborations.
This event is part of the World Advanced Therapeutics Summit South Korea, so attendees will also have access to sessions for the World Cell & Gene Therapy Summit South Korea.
Download the Official Agenda to Explore:
공식 아젠다를 다운로드하여 다음 내용을 확인하세요:
- Your one-stop forum to de-risk, develop, and collaborate to advance RNA therapeutics and vaccines
- Insights from 20+ Korean-based and international speakers
- 20+ Data-driven case-studies across RNA Discovery to clinic and manufacturing
- Unrivalled networking opportunities with experts working on RNA, cell and gene therapies
Unmissable Event Highlights
놓칠 수 없는 행사 하이라이트
Optimize mRNA Design
Optimize your mRNA sequence design and manufacturing of circular RNA modalities to superior functional validation with insights from Circurna, RZnomics and National Taiwan University
Advance RNA & LNP Technologies
Advance your RNA & LNP platform technologies to achieve clinical success in vivo CAR and widen the therapeutic barriers, with key progress updates from Abogen Biosciences and Medici Bio
Overcome Small-Scale Design Challenges
Overcome the challenges of small-scale design to GMP manufacturing capability for the personalized cancer vaccines and their potential marketability through shared discussions with LG Chem and Aston Sci
Gain Strategies to Accelerate mRNA
Gain practical strategies for accelerating mRNA process, quality control and regulatory alignment strategies across APAC to ensure scalability and cost-effectiveness across development with insights from Meiji Seika Pharma and RNA Australia
Achieve LNP Composition
Achieve the best LNP composition and platform to ensure organ-specific targeting, tolerability and safety with key academic insights from Tel-Aviv University, Yeungnam University and Seoul National University
Who Will You Meet?
참석 기업
Connect and collaborate with international and local Korean biotech, pharma and key solution experts to build new alliances through strategic discussions and work together to advance Korean RNA medicines to patients faster
What Your Peers Have to Say
This meeting will serve as a key scientific catalyst, accelerating the expansion of mRNA-based therapeutics into cancer vaccines, immuno-oncology, and autoimmune disease treatments
Kug Hwa Lee, Director, MediciBio
I believe that orchestrated collaboration and communication across companies involved in mRNA manufacturing, LNP development, and payload development are essential for the rapid advancement of the mRNA therapeutics field.
I look forward to building momentum for these partnership opportunities through this conference
Jaehyun Choi, Chief Executive Officer, Genexine
Explore the Agenda
Hear the latest technology innovations taking place within South Korea and gain exclusive insights on the progress in development globally.
Partner With Us
Position yourself alongside other leading solution providers to ensure your company is the go-to service providers for Korean Advanced Therapeutics leaders.
Join Biopharma Experts
Be part of the hottest conversations with like-minded scientists, C-level executives, heads, managers, VPs, and more across discovery, clinical and CMC functions.